RxDoctor Payments Data

Ann Patterson

Endocrinology, Diabetes & Metabolism · Sewickley, PANPI 1538701347

Payments from drug & device makers

$810in general payments, 2019–2025

Across 33 payments — averaging $24.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$188
  • Novo Nordisk$93
  • Ascendis Pharma Endocrinology Inc$72
  • Bayer$65
  • Tandem Diabetes Care, Inc.$60
  • Insulet Corporation$52
  • plus $281 from 10 others

What the payments were for

  • Food & beverage$810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$810 in reported general payments places this provider in the 40th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$17,430
Medicare patients
97
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$51,684
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$1,465
Albuterol Sulfate HfaAlbuterol Sulfate14$900
Potassium Chloride41$855
Gabapentin23$839
Losartan Potassium28$745
Oxycodone Hcl49$743
Betamethasone Dipropionate11$716
Pantoprazole Sodium32$670
Rosuvastatin Calcium37$648
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$539
Atorvastatin Calcium34$481
Pregabalin14$462
Metoprolol Succinate41$450
RivastigmineRivastigmine Tartrate11$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$36136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

Other endocrinology, diabetes & metabolism in Sewickley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →